Conditions: HIV Related Insulin Resistance Protease Inhibitor Related Insulin Resistance Endoplasmic Reticulum Stress
Keywords: HIV Protease inhibitor insulin resistance Tauroursodeoxycholic acid
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 27
Healthy volunteers: no

Brief summary:
Rates of cardiovascular disease and diabetes are more than 2-fold greater in HIV infected people than the general population. Protease inhibitor booster antiretroviral therapy (PI-ART) which is used by \~50% of HIV infected people in the USA is an established risk factor for diabetes. Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile salt, improves insulin sensitivity in HIV uninfected subjects, although the mechanisms for these benefits are unclear. This study will explore the hypothesis that TUDCA will improve insulin action in people with HIV who are receiving PI-ART. Further, this project will clarify the molecular mechanisms responsible for these improvements potentially benefiting society, irrespective of HIV status.

Detailed description:
The purpose of this study is to determine if, and through which mechanisms, tauroursodeoxycholic acid improves insulin sensitivity in subjects with protease-inhibitor associated insulin resistance.

The investigators will perform body composition analysis by using a DEXA machine, liver fat measurement by using an MRI, and hyperinsulinemic euglycemic clamp procedures in 48 HIV infected, insulin-resistant/prediabetic subjects before and after 30 days of treatment with tauroursodeoxycholic acid or matching placebo. Biopsies of adipose tissue and skeletal muscle will be taken during fasting conditions and during insulin infusion, before and after treatment to measure markers of endoplasmic reticulum stress and thyroid hormone deiodinase.

Outcome measures:

The primary outcome measures will be change in glucose clearance during insulin infusion, change in markers of endoplasmic reticulum stress and change in content of D2 in muscle.

Arms:
arm 1: This group will receive 1.75 grams per day of tauroursodeoxycholic acid given once daily for 30 days. arm 2: This group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.

Interventions: intervention 1: Tauroursodeoxycholic acid intervention 2: Placebo tablet
Intervention descriptions: intervention 1: The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days. intervention 2: The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.

Protocol document:
Prot_SAP_000.pdf: 
IM 
WASHINGTON UNIVERSITY  [Company address] 
Tauroursodeoxycholic Acid for Protease-inhibitor 
Associated Insulin Resistance              
NCT#01877551  
3/6/2019 
 
 
 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
1 
 
 
 
 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
2 
 
TABLE OF CONTENTS 
A 
INTRODUCTION ...............................................................ERROR! BOOKMARK NOT DEFINED. 
A1 
STUDY ABSTRACT.................................................................. ERROR! BOOKMARK NOT DEFINED. 
A2 
PRIMARY HYPOTHESIS ........................................................... ERROR! BOOKMARK NOT DEFINED. 
B 
BACKGROUND ..................................................................ERROR! BOOKMARK NOT DEFINED. 
B1 
PRIOR LITERATURE AND STUDIES .......................................... ERROR! BOOKMARK NOT DEFINED. 
B2 
RATIONALE FOR THIS STUDY ......................................................................................................... 6 
C 
STUDY OBJECTIVES ........................................................................................................................ 7 
C1 
PRIMARY AIMS .............................................................................................................................. 7 
C2 
SECONDARY AIM ........................................................................................................................... 7 
D 
INVESTIGATIONAL AGENT .......................................................................................................... 8 
D1 
PRECLINICAL DATA ....................................................................................................................... 8 
D2 
DOSE RATIONALE AND RISK/BENEFITS ....................................................................................... 11 
E 
STUDY DESIGN AND PROCEDURES .......................................................................................... 12 
E1 
OVERVIEW OR DESIGN SUMMARY ............................................................................................... 12 
E2 
SUBJECT SELECTION  ................................................................................................................... 13 
2.a 
Inclusion Criteria .................................................................................................................... 13 
2.a 
Exclusion Criteria ................................................................................................................... 13 
2.c        Randomization Scheme ........................................................................................................... 18 
G 
STATISTICAL PLAN AND STUDY TIMETABLE ...................................................................... 18 
G1 
ANALYSIS PLAN SIZE  .................................................................................................................. 18 
G2 
POWER ESTIMATES ...................................................................................................................... 18 
G3 
POWER ESTIMATES FOR EACH ENDPOINT ..................................................................................... 18 
G4 
TIMETABLE OF STUDIES ............................................................................................................... 19 
H 
PATIENT SAFETY AND MONITORING ..................................................................................... 19 
H1 SUBJECT RISK AND PROTECTION AGAINST RISK ................................................................................ 19 
H2 COMPLIANCE .................................................................................................................................... 20 
H2 DATA AND SAFETY MONITORING .................................................................................................... 20 
 
L 
ATTACHMENTS .............................................................................................................................. 21 
L1 
ANIMAL TOXICITY DATA ............................................................................................................. 21 
M 
REFERENCES ................................................................................................................................... 25 
 
 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
3 
 
 
A1. Abstract 
The introduction of protease-inhibitor based antiretroviral therapy (PI-ART) has reduced the mortality 
associated with HIV infection (HIV+). Unfortunately, PI-ART use is a major risk factor for insulin 
resistance, an important risk factor for diabetes and coronary heart disease (CHD). 
Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile salt, improves insulin sensitivity in 
insulin resistant people who do not have HIV. We have found that TUDCA markedly ameliorates 
ritonavir-induced insulin resistance in human myotubes and mice. The mechanism(s) responsible for 
these TUDCA-induced metabolic improvements are unclear, but could be related to: 1) TGR5 receptor 
activation, which upregulates cellular factors in muscle, including type 2 deiodinase (which increases 
intracellular triiodothryonine) and PGC-1 that increase mitochondrial biogenesis and fatty acid oxidation 
and/or 2) acting as chaperones that reduce endoplasmic reticulum (ER) stress by assisting protein 
folding. Initiation of ritonavir-boosted PI-ART worsens insulin sensitivity in HIV+ people and induces 
markers of ER stress in adipose tissue. We propose to perform a double-blind, randomized, controlled 
trial to determine if TUDCA improves insulin sensitivity in insulin-resistant, HIV+ people receiving PI-
ART and to clarify the molecular mechanisms responsible for these improvements. We will randomly 
assign 48 insulin-resistant, HIV+ subjects to either placebo or TUDCA (1.75g/day x 30 days) and will 
measure multi-organ insulin sensitivity before and after the intervention by using a multistage 
hyperinsulinemic euglycemic clamp with infusion of stable isotope labeled tracers. To clarify the 
mechanisms responsible for the anticipated improvements in insulin sensitivity, we will examine the 
effect of TUDCA on TGR5 activation (type 2 deiodinase expression) in skeletal muscle biopsies and on 
ER stress by measuring Grp78 in adipose tissue biopsies taken before and after TUDCA 
administration. The results from this study will determine not only whether TUDCA may be effective for 
treatment of PI-associated insulin resistance but is also expected to identify new pathways by which 
TUDCA exerts insulin sensitizing effects. In addition to improving clinical care of people with HIV, the 
findings of this study may allow development of new drugs for treatment of type 2 diabetes. 
Purpose of Study Protocol 
The overall goals of this proposal are to evaluate whether TUDCA administration improves insulin sensitivity in 
HIV+ people receiving ritonavir-boosted, PI-ART, and to examine the potential cellular mechanisms through 
which TUDCA imparts its metabolic benefits. These findings will reveal novel molecular mechanisms by which 
TUDCA exposure improves insulin resistance in people living with HIV. Specifically, we will conduct  a double-
blind placebo-controlled trial to examine the effect of TUDCA (1.75g x 4 weeks) on multi-organ insulin 
sensitivity, muscle TGR5 signaling, and markers of adipocyte ER stress in 48 insulin-resistant, HIV+ men and 
women  receiving ritonavir-containing PI-ART 
B. Background  
B1. Prior Literature 
HIV infection is associated with increased risk of metabolic abnormalities. HIV+ individuals have a 2-4 fold 
greater risk for developing type 2 diabetes (T2DM) than the general population (1, 2) as well as dramatically 
increased rates of cardiovascular disease (CVD) (3, 4). Traditional risk factors including insulin resistance (IR) 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
4 
 
are key predictors of CVD events in chronic HIV infection, and are especially important given the greater 
prevalence of T2DM in HIV-infected people (4-7). Protease-inhibitor based antiretroviral therapy (PI-ART) use, 
in particular use of ritonavir (RTV), is an established risk factor for development of IR and T2DM (1, 8, 9). Several 
PIs impair insulin-mediated stimulation of glucose uptake and suppression of glucose production and reduce 
insulin secretion (10-13). PIs can compete with glucose for binding to the facilitative glucose transporters 
expressed on skeletal myocytes (11). However, other intracellular molecular mechanisms are also likely at play. 
Nucleoside reverse transcriptase inhibitors are associated with reduced expression of genes critical in adipocyte 
development and mitochondrial biogenesis (PGC-1) (14-16).  Indeed, we, and others, have reported a reduced 
capacity for fatty acid (FA) oxidation in HIV+ people with IR (17). Reduced lipid oxidation may promote tissue 
lipid accumulation and insulin resistance (17, 18). High concentrations of some PIs, including ritonavir, atazanavir 
and lopinavir, may also increase ER stress (19-25), which has been linked to development of insulin resistance 
(26-28), but this has yet to be demonstrated in vivo. Thus, the etiology of insulin resistance in treated HIV is likely 
multifactorial.  
Drug and lifestyle intervention are less effective in cART-associated insulin resistance. Lifestyle change 
is recommended for obese, HIV+ insulin-resistant people (29, 30), however Engelson et al found that 7% weight 
loss did not improve IR in obese, HIV+ women (31). While exercise improves IR in HIV+ subjects, long-term 
changes in exercise habits are hard to maintain (32). Metformin and thiazolidinediones (TZDs) improve insulin 
sensitivity in HIV+ subjects (33, 34) but these drugs are associated with several side effects. Metformin often 
causes diarrhea and worsens subcutaneous fat loss, while TZDs may increase the risk of myocardial infarction, 
osteoporosis and worsen abdominal adiposity (33, 35-41). Furthermore, recent data indicates that HIV infected 
people, particularly those receiving PIs, have poorer glycemic responses to anti-diabetic drugs than HIV 
uninfected people (42). New, effective therapies are badly needed. 
Bile acids (BAs) as an alternative therapy to increase insulin sensitivity. Studies conducted in cultured cells 
or in mouse models of obesity suggest that exogenous BAs improve insulin sensitivity (26-28). Members of our 
group performed a double-blind, randomized, placebo-controlled trial to examine the effects of the bile acid 
tauroursodeoxycholic acid (TUDCA) (donated by Bruschettini S.r.l.), which is approved for treatment of 
cholestatic liver disease in Europe, on insulin sensitivity in HIV uninfected, insulin-resistant subjects (43). Insulin 
sensitivity was measured by using clamp protocols identical to that contained in this proposal. Treatment with 
1.75 g/day of TUDCA for 30 days (a dose and duration identical to that proposed in this application) increased 
the hepatic insulin sensitivity index (Fig 1A) by 42% (0.86±0.17 vs 1.22±0.16 100/µmol/min x µU/ml, P<0.01) 
and insulin-sensitivity in skeletal muscle (Fig 1B) by 22% (Pre 48±5 vs Post 59±6 µmol/kgFFM/min, P<0.01 (Fig 
1). Western blot analyses performed on muscle biopsies from these subjects by Dr. Finck’s lab, found that insulin 
receptor substrate-1 (IRS-1) phosphorylation and signaling (p-AKT) also improved (Fig 2), indicating that TUDCA 
administration ameliorates skeletal muscle insulin resistance at a molecular level. Furthermore, these and other 
studies conducted by Dr. Finck, found no indication that ER stress signaling was activated in skeletal muscle of 
insulin resistant subjects compared to insulin sensitive controls or that TUDCA reduced ER stress in  


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
5 
 
 
these subjects (43). This raises the possibility that the effects of TUDCA are independent of effects on ER stress 
signaling. 
Molecular actions of bile acids. The mechanism(s) whereby BAs mediate metabolic improvements are unclear 
but may include [1] activating cell surface receptors that activate intracellular signal transduction cascades (27, 
28, 44-47), [2] acting as chaperones that reduce endoplasmic reticulum (ER) stress, and/or [3] serving as ligands 
for nuclear receptors that regulate gene transcription. This proposal is designed to address the two former 
mechanisms since, unlike other BAs, TUDCA has not been shown to have high affinity for any members of the 
nuclear receptor superfamily, and thus, this mechanism will not be evaluated. 
TGR5, which is expressed in muscle, fat and liver, might mediate the metabolic effects of BAs. Recent 
work has suggested that BAs, including TUDCA, bind and activate the cell surface G-protein-coupled receptor 
TGR5. Several BAs, including TUDCA, exhibit high affinity for TGR5 and knockout of TGR5 abolishes the 
intracellular signaling response to BAs. In C57BL6 mice (with normal 
TGR5 activity), activation of TGR5 by BAs increases intracellular 
deiodinization of thyroid hormone by type 2 deiodinase (D2), converting 
tetra-iodothyronine (T4) to the more biologically active tri-iodothyronine 
(T3) which binds the iodothyronine receptor (TR) (44). This increases 
energy expenditure and fatty acid oxidation by stimulating expression 
of genes encoding fatty acid transport and oxidation (CPT-1) enzymes, 
and promoting mitochondrial biogenesis (PGC-1) (Fig 3). Studies in 
human skeletal muscle cells also showed that these effects were 
translatable to humans as well (44). Our preliminary data show that 
TUDCA administration for 30 days increases expression of D2 in 
skeletal muscle in insulin-resistant, HIV uninfected subjects (see 
Innovation). This proposal will evaluate the effects of TUDCA on 
markers of TGR5 action in skeletal muscle and adipose tissue of HIV+ 
subjects receiving PI-ART, clarifying whether this pathway may have 
therapeutic potential for other insulin resistant states. The proposed 
 
Fig 3. Mechanisms through which 
TUDCA may improve substrate 
metabolism.  


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
6 
 
studies will also use molecular genetic approaches to define whether TGR5 activation is required for the insulin 
sensitizing effects in skeletal myotubes exposed to PIs. 
TUDCA may act as a chemical chaperone to assist with protein folding and reduce ER stress. During 
periods of cellular 
stress such as drug 
exposure 
to 
PIs, 
chronic viral infection 
(e.g. hepatitis C), or 
obesity, 
protein 
misfolding 
may 
occur in the ER and 
induce the unfolded 
protein 
response 
(UPR), which has 
been linked to the 
development 
of 
insulin 
resistance 
(27, 28, 48-50). The 
UPR activates three 
signaling cascades 
(Fig 4).  
1) Release of the 
chaperone 
Bip 
(Grp78) into the ER  
to 
assist 
protein 
folding 
 
and 
attenuate general protein synthesis by activation of PER- kinase 
(PERK), leading to phosphorylation of eukaryotic initiation factor 2α 
(eIF2α).  
2) Activation of inositol-requiring enzyme 1 (IRE-1), resulting in alternative splicing the XBP-1 transcript and the 
expression of XBP-1 protein, which in turn induces expression of a wide range of chaperone proteins which 
ameliorate protein misfolding. IRE-1 also activates JNK worsening insulin resistance (27, 51).  
3) Release of bound activating transcription factor-6 (ATF-6), which induces XBP-1 expression and upregulates 
production of molecular chaperones. Through mechanisms that are still mostly unclear, TUDCA is known to 
reduce ER stress and is thought to act as a chemical chaperone to facilitate proper folding of misfolded proteins 
(28, 52, 53).  
Besides its critical role in maintaining ER homeostasis, the UPR has an important impact on metabolic regulation 
and insulin signaling. Both defective and excessive activation of ER stress pathways have been linked to JNK 
activation, inflammation, and insulin resistance in several mouse models (17, 22, 23).  Similarly, interventions 
that reduce ER stress, including TUDCA, improve insulin resistance in animal models (27, 28) and HIV uninfected 
xBP1 
protein 
 
 
 
 
 
PERK 
ATF6 
IRE1 
P 
P 
P 
P 
eIF2αPeIF2α 
ATF cleavage 
by SP1 and SP2 
Splicing of 
XBP1 mRNA 
Inhibition of 
Protein translation 
 ATF4 
N-terminal 
fragment of 
ATF6 
 
UPR target genes: BIP/Grp78, Grp94, pEIF2a/EIF2a, IRE-1, PERK, 
spliced Xbp1, Chop, ATF6, ATF4 
                           ER stress: 
Drugs, viral infection, glucose deprivation, ?ART 
Protein misfolding 
Chaperone 
proteins, 
TUDCA 
(-) 
(+) 
Fig 4. Schematic of ER stress and the UPR 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
7 
 
human subjects (43). Both HIV and PIs may activate the UPR and thereby contribute to metabolic dysfunction 
(19, 24, 54).  
However, there is also evidence that the ameliorative effects of TUDCA on ER stress are not related to the 
insulin-sensitizing effects of this agent. For example, in Kars et al., we found that skeletal muscle glucose 
disposal and insulin signaling were improved in obese subjects, but found no evidence that ER stress was 
activated in skeletal muscle of these subjects or that TUDCA attenuated ER stress in this tissue (43). Our new 
preliminary data indicate that TUDCA improves insulin-stimulated glucose uptake in ritonavir-treated human 
skeletal myocytes, but we found no evidence that RTV caused ER stress in these cells. This could suggest other 
mechanisms whereby TUDCA elicits its effects. Therefore this proposal will clarify whether markers of ER stress 
are reduced in skeletal muscle and adipose tissue of HIV+ subjects after administration of TUDCA.  
B2. Rationale for Study: 
HIV+ people receiving PI-ART have an increased risk of DM and a blunted response to antidiabetic 
pharmacotherapy. Bile acids improve insulin sensitivity in animals and HIV seronegative humans, upregulate 
mitochondrial biogenesis, increase fatty acid oxidation, and may reduce ER stress, all of which are likely to have 
favorable metabolic effects. This proposal will use state of the art techniques to examine the hypothesis that the 
bile acid TUDCA will improve insulin-stimulated glucose disposal (i.e. insulin-sensitivity in skeletal muscle) in 
HIV+, insulin-resistant subjects receiving PI-ART. Further, we will clarify the cellular and molecular mechanisms 
by which TUDCA confers its benefits to test two hypotheses focused on the TGR5 and ER stress pathways. The 
mechanistic findings of this proposal will benefit insulin-resistant subjects irrespective of HIV serostatus. 
Study Objectives 
The overall goals of this proposal are to evaluate whether TUDCA administration improves insulin sensitivity in 
HIV+ people receiving ritonavir-boosted, PI-ART, and to examine the potential cellular mechanisms through 
which TUDCA imparts its metabolic benefits. These findings will reveal novel molecular mechanisms by which 
TUDCA exposure improves insulin resistance in people living with HIV. Specifically, we will conduct  a double-
blind placebo-controlled trial to examine the effect of TUDCA (1.75g x 4 weeks) on multi-organ insulin sensitivity, 
muscle TGR5 signaling, and markers of adipocyte ER stress in 48 insulin-resistant, HIV+ men and women  
receiving ritonavir-containing PI-ART 
The following Specific Aims will be evaluated: 
1. 
Determine the effect of TUDCA administration on multi-organ insulin sensitivity. 
We hypothesize that TUDCA will improve in vivo insulin sensitivity more than placebo in skeletal 
muscle (glucose uptake) (primary endpoint), liver (suppression of glucose production), and adipose 
tissue (suppression of lipolysis), assessed in vivo by using a two-stage euglycemic-hyperinsulinemic 
clamp procedure with stable isotope tracer infusion and in the cellular components of the insulin 
signaling cascade (phosphorylation of IRS1 and Akt) and factors that inhibit insulin signaling 
(phosphorylation of JNK) in muscle and adipose tissue obtained by percutaneous biopsy .  
2. 
Evaluate the effect of TUDCA on TGR5 activation and the role that this plays in the 
insulin sensitizing effects of TUDCA. We hypothesize that TUDCA treatment will increase skeletal 
muscle expression of D2 (primary endpoint), PGC-1α, and other markers of TGR5 activation. In 
addition, we hypothesize that in vitro knockdown of TGR5 will attenuate the beneficial effects of TUDCA 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
8 
 
on PI-induced insulin resistance. 
3. 
Determine the effect of TUDCA on endoplasmic reticulum stress in HIV+ men and women 
receiving PI-ART. We hypothesize that TUDCA will reduce adipose tissue markers of ER stress and 
inflammation (BIP/Grp78 (primary endpoint), Grp94, pEIF2a/EIF2a, IRE-1, PERK, spliced Xbp1, Chop, 
ATF6, ATF4, and phosphoJNK)  
 
The results from this study will elucidate new intracellular pathways by which TUDCA exerts insulin 
sensitizing effects among HIV+ men and women receiving PI-ART, who represent a population at very 
high risk for diabetes and CHD.  
 
 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
9 
 
D Investigational Agent 
D1. Preclinical Data 
TUDCA improves RTV-induced glucose intolerance in vivo. The primary endpoint of this application 
is to determine whether TUDCA will improve insulin-stimulated glucose disposal in HIV+ subjects treated 
with PI-ART. Ritonavir (RTV) boosted, PI-ART is the most commonly used PI therapy in our local HIV+ 
subjects (55) and is known to impair insulin sensitivity and risk of development of the metabolic syndrome 
(13, 56, 57). To begin to test the efficacy of TUDCA at ameliorating RTV-induced insulin resistance, wild-
type, lean C57/BL6 mice were fasted 
overnight 
and 
then 
injected 
intraperitoneally TUDCA (500 mg/kg) or 
vehicle, 
one 
hour 
before 
receiving 
intraperitoneal RTV (1 mg/kg). This low 
dose of RTV dose, ~10% of that usually 
used in these experiments, was chosen 
because it is expected to achieve plasma 
concentrations similar to that seen with 
clinical use of ritonavir (10).  An 
intraperitoneal glucose tolerance test 
(IPGTT) was performed 1 hour later (Fig 
5A). Glucose AUC was greater in RTV 
(27477±1060 mg/dl x 120min), than the 
vehicle (22100±316, P=0.001), TUDCA 
(22500±928, P=0.001) and RTV+TUDCA 
(22902±372, P=0.001) groups. We also 
examined insulin signaling in fasted mice 
treated with TUDCA and RTV as in the 
IPGTT, but injected with insulin 10 min 
prior to sacrifice (n=2). In this pilot 
experiment, 
RTV 
treatment 
led 
to 
diminished Ser473 phosphorylation of Akt 
in 
gastrocnemius 
muscle, 
whereas 
TUDCA pretreatment reversed this effect 
of RTV (Fig 5B). These results indicate 
that TUDCA almost completely ameliorates RTV-induced glucose intolerance  and impairments in insulin 
signaling in vivo. 
TUDCA ameliorates RTV-induced insulin resistance in vitro. We examined whether TUDCA would 
reduce insulin resistance induced by RTV in human skeletal myotubes. Muscle satellite cells were 
isolated from vastus lateralis muscle biopsies obtained from HIV-seronegative subjects and were 
differentiated into myotubes for 10 days by Dr. Chen,  as described previously (58, 59)  On day 11, 
myotubes were then incubated with or without TUDCA (400 µg/ml) for 6 hours. RTV (10 µM) or vehicle 
(DMSO) were then added to the culture media and cells were incubated for ~8 hrs. 3H-2-deoxy glucose 
 
 
Fig 5 A. Plasma glucose concentration during 
IPGTT and [B] insulin-mediated phosphorylation 
of Akt Ser473 in skeletal muscle 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
10 
 
(2DG) was measured in the absence (basal) or presence of insulin (1 µg/ml). As shown in Fig 6, RTV 
reduced glucose uptake by ~50%, but this effect was partially reversed with pre-incubation with TUDCA. 
In this pilot study, we specifically chose RTV concentrations were 2-3x that seen with boosting-doses to 
allow us to better delineate a potential maximum benefit of TUDCA on RTV-induced insulin resistance.  
We also examined the effects of TUDCA on 
ER stress markers in human myocytes that 
had been treated with PIs (Fig 7). At the 
same doses and durations that impair basal 
and insulin stimulated glucose uptake (Fig 
6), 
RTV 
did 
not 
activate 
EIF2a 
phosphorylation or Bip protein abundance 
(Fig 7). Other groups have shown that PIs 
induce ER stress in adipocytes and 
macrophages in vitro (19, 60). Indeed, 
lopinavir co-induced insulin resistance and 
ER stress in human adipocytes (19). On the 
other hand, the lack of effect of RTV on ER 
stress in skeletal myocytes is consistent 
with of the work of several groups showing 
that obesity-related insulin resistance is not 
associated with increased ER stress in skeletal muscle, but is associated with increased ER stress in 
liver and adipocytes (27, 43).  These findings suggest that the insulin-sensitizing effects of TUDCA may 
be independent of its anti-ER stress mode of action. 
Initiation of PI-ART induces ER stress in adipose tissue but not skeletal muscle. To expand upon 
this point, we determined whether initiation of PI-ART containing ritonavir led to indications of ER stress 
in humans. We performed western-blots for Grp78(Bip), EIF2α and phosphorylated EIF2α (pEIF2α) on 
skeletal muscle and adipose tissue biopsies from 7 HIV+ patients (5M, BMI 26±1kg/m2), naïve to ART, 
with asymptomatic HIV infection, before, and 4 months after initiation of PI-ART (6ATV/RTV, 1 DRV/RTV, 
all receiving DF+FTC), which increased HOMA (1.7±0.1 vs 2.4±0.4, P=0.09) in these subjects. Although 
insulin resistance was worsened by PI initiation, skeletal muscle abundance of GRP78 and 
phosphorylated EIF2a was not affected by PI administration (Fig 8), which is consistent with our in vitro 
data.  
* 
+ 
 
Fig 7. Effect of RTV±TUDCA on ER stress markers in 
human myotubes.  
Fig 9. Relative change 
in adipose tissue Grp78 
content and p-eIF2α: 
eIF2α ratio after 4 
months of PI-ART . 
* P<0.05, 
+ P=0.07 
 
Fig 6. Effect of RTV±TUDCA on 2-Deoxyglucose 
uptake in human myotubes. Ins, insulin; T, TUDCA. 
* P<0.01 vs vehicle. + P<0.02 vs conditions without 
TUDCA.  
 
 
 
 
Fig 8. Skeletal muscle Grp78 abundance and 
peIF2α/peIF2α ratio before and after 4 months of PI-ART. 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
11 
 
In contrast, in adipose tissue, Grp78 abundance and the PeIF2α: eIF2α ratio increased after 4 months of 
PI-ART (Fig 9). These results suggest that PI-ART induces ER stress in adipocytes but not skeletal 
muscle in vivo in HIV+ humans. Recent work has suggested that dysfunctional adipose tissue, a term 
that encompasses a broad range of metabolic and inflammatory perturbations including ER stress, is 
involved in systemic insulin resistance by affecting circulating concentrations of metabolites, adipokines, 
and pro-inflammatory mediators. We have hypothesized that administration of TUDCA will reduce 
indications of ER stress in adipose tissue and will determine whether these changes are associated with 
improvements in multi-organ insulin sensitivity.  
 
TUDCA increases expression of deiodinase 2 in skeletal muscle. Our alternative hypothesis is that 
TUDCA may be improving insulin sensitivity after RTV treatment via 
other mechanisms. Previous work has demonstrated that TUDCA is a 
potent activator of TGR5 signaling in human skeletal myocytes in vitro 
(44). To determine whether markers of TGR5 activation were also 
induced in human muscle at therapeutic doses, in collaboration with 
Dr. Abumrad’s laboratory, we performed quantitative RT-PCR to 
quantify D2 mRNA expression in skeletal muscle biopsies from 
subjects treated with TUDCA (1.75/day, N=9) or placebo (N=9) for 30 
days (Fig 10) (43). A strong trend towards increased expression of D2 
was detected after 30 days of treatment with TUDCA (P=0.057), but 
was unchanged by placebo. These data provide evidence that TUDCA 
may impart its metabolic actions in part by increasing expression of D2 
through TGR5 in skeletal muscle in humans in vivo. Our proposal will 
determine whether use of TUDCA causes similar changes in the 
setting of treated HIV, whether other TGR5 targets are activated by 
TUDCA in skeletal muscle in vivo (PGC1, CPT-1), and will use 
sophisticated in vitro approaches to define whether TGR5 is required 
for the beneficial effects of TUDCA on RTV-induced insulin resistance. These findings could potentially 
have a major impact on our understanding of how TUDCA improves insulin sensitivity in humans and 
assist with development of another class of antidiabetic agents. 
In summary, our preliminary data show: 
1. RTV-induced glucose intolerance (and insulin resistance) is improved by treatment with TUDCA in 
mice.  
2. RTV induces insulin resistance, but not ER stress, in human skeletal myocytes and RTV-induced 
insulin resistance is improved by treatment with TUDCA.  
3. Markers of ER stress are increased in adipose tissue, but not skeletal muscle, biopsies of ART-naïve 
HIV+ subjects 4 months after initiation of PI-ART.  
4. Treatment of insulin-resistant, HIV uninfected, human subjects with 1.75 g of TUDCA for 30 days 
induces markers of TGR5 activation in skeletal muscle.  
The proposed mechanisms of insulin sensitization by TUDCA are not mutually exclusive and both 
pathways could be involved. TUDCA clearly elicits rapid ameliorative effects on ER stress in response to 
a variety of stimuli in liver and adipose tissue. However, prolonged (4 week) treatment with TUDCA 
* 
Fold-change in D2 
expression
Placebo
TUDCA
Fig 10. Fold change 
in D2 expression 
after placebo or 
TUDCA. *P=0.057 vs 
placebo 
* 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
12 
 
improves skeletal muscle insulin sensitivity in human obese subjects, who did not exhibit an activation of 
the ER stress response in that tissue (43). While the effect on skeletal muscle insulin sensitivity could be 
explained by peripheral effects on hepatic or adipose tissue metabolism or adipokine secretion, these 
effects could also be mediated by activation of TGR5 signaling in skeletal muscle. TUDCA may also have 
both acute and chronic actions or alternatively could be affecting ER stress pathways in a tissue-specific 
manner.  By clarifying the mechanism(s) responsible for improvements in insulin sensitivity with TUDCA, 
this proposal will improve the quality of care for people living with HIV, but also benefit those with insulin 
resistance but without HIV. 
 
D.2 Dose Rationale and Risk/Benefit 
Natural bile salts consist of a family of amphipathic steroids produced by cholesterol metabolism in the 
liver. Bile salts are classified as primary (synthesized in the liver) or secondary (produced by bacterial 
transformation of bile salts within the gut). In man, primary bile salts consist of cholic acid (CA) and 
chenodeoxycholic acid (CDCA) and the secondary bile salts deoxycholic acid (DCA) and lithocholic acid 
(LCA). Ursodeoxycholic acid (UDCA) is an epimer of CDCA and is normally present in small amounts in 
human bile (0-5% of total pool) however taurine-conjugated UDCA (TUDCA) represents the physiologic 
form in which UDCA is secreted in bile. The taurine conjugation makes UDCA slightly more water soluble 
and makes precipitation of TUDCA within the gallbladder improbable due to the acidic conditions.  
TUDCA has been licensed for the treatment of cholesterol gallstones and for therapy of chronic 
cholestatic liver disease in Europe since 1991 and is used at a dose of 10-20 mg/kg/day depending on 
the indication. Chronic toxicity has been studied in dogs for up to 26 weeks with treatment of up to 400-
600 mg/kg/day (30 x that of the proposed dose) with no observed toxicity. Rats treated with 2-20 times 
the proposed dose showed no evidence of carcinogenic effects after 24 months of treatment. (Please 
see appendix).  
Several recent studies indicate that 1.75g/day of TUDCA as proposed in this application is a safe and 
likely effective dose for insuiln resistance. In a recent study 10 obese, insulin-resistant adults received 
1.75 g/day of TUDCA for 4 weeks with no adverse events. (43) A cohort of subjects with primary biliary 
cirrhosis were treated with 500-1500 mg/day of TUDCA for 6 months, with diarrhea reported as the only 
side-effect. Several human studies have shown that use of TUDCA is well tolerated in many chronically 
ill populations including amyloidosis(61), primary biliary cirrhosis (62-65) and liver transplant (66). Most 
experience with TUDCA has been in the use of this agent with liver disease, predominantly primary 
biliary cirrhosis (PBC). Crosignani et al treated 24 subjects with PBC with 500mg, 1000mg, or 1500mg 
of TUDCA per day. (63) All patients showed improvements in liver function tests with the greatest 
improvements seen in the 1000mg and 1500mg doses. The only reported side effect was diarrhea. The 
predominant side effects reported with TUDCA use in human studies have been diarrhea, headache, 
dyspepsia or abdominal pain. We exclude all patients with prior gallbladder disease or with diarrhea.  
 
 
In summary, TUDCA has been tolerated at similar dose in humans with a variety of chronic medical 
conditions, with the major side-effects being mild diarrhea. The balance of the clinical information 
suggests that this drug is well tolerated and could have important health benefits for this study 
population. There are no known interactions between bile acids and antiretroviral drugs.  


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
13 
 
 The dose proposed in this study is 1.75 g/day which will correspond to an average dose of 15-20 
mg/kg/day. We wish to use this dose because this is a dose that has been shown to be effective in 
other human studies with few side effects. (43)   
Based on available animal and human data, other than the potential for diarrhea, TUDCA appears to be 
very well tolerated even at doses 30-fold greater than that proposed. We therefore believe that this 
agent has shown very limited toxicity in humans but could confer significant cardiometabolic benefit.  
E. Study Design 
E.1  
Specific Aim 1: Determine the effect of TUDCA on multi-organ insulin sensitivity.  
Multi-organ insulin sensitivity will be assessed by performing euglycemic clamps, in conjunction with 
stable isotope labeled tracer infusion (section 4) and tissue biopsies, before and after placebo or TUDCA. 
We have predicted that treatment with TUDCA will improve skeletal muscle glucose disposal and insulin 
signaling in HIV+ subject treated with PI-ART.    
1. Subjects.  The study population will consist of two groups of patients (Fig 11): 
Group 1 will consist of 24 subjects with HIV+ receiving RTV boosted PI-ART who have insulin resistance 
as evidenced by the presence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or 
HOMA-IR>3.0 who will receive TUDCA 1.75g/day for 30 days. 
Group 2 will consist of a total of 24 subjects with HIV+ receiving RTV boosted PI-ART who have IFG, 
IGT or HOMA>3.0 who will receive matching placebo for 30 days. 
 
 
 
 
 
 
 
 
 
 
 
2. Study Subjects:  
1.75g TUDCA x 30 days 
Fig 11. Experimental schema 
24 insulin resistant, HIV+ 
subjects (Group 1) 
24 insulin resistant, HIV+ subjects 
(Group 2) 
Oral glucose tolerance test, lipid panel, CMP, CBC, CD4,  
Body composition (DEX, MRI) Intrahepatic and Intramyocellular lipid content (MRS) 
Euglyemic hyperinsulinemic clamp with adipose and muscle biopsies. 
Screening: Oral glucose tolerance test, lipid panel, CMP, CBC, Body composition (DEX, MRI) 
Intrahepatic and Intramyocellular lipid content by magnetic resonance spectroscopy (MRS) 
Euglyemic hyperinsulinemic clamp with adipose and muscle biopsies. 
Placebo x 30 days 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
14 
 
E 2.a The inclusion criteria are: 1) aged 18-70 yrs, 2) body-mass index of 20-40 kg/m2, 3) have 
documented HIV infection with positive anti-HIV antibody and Western blot, 4) undetectable viral load for 
at least 6 months prior to enrollment, 5) hemoglobin > 10g/dl, 6) have abstained from agents that affect 
glucose and lipid metabolism for at least six months prior to enrollment (e.g. GH, glucocorticoids, omega-
3-fatty acids, metformin), 7) have unchanged prescription medications for at least 3 months prior to 
enrollment, and 8) all subjects must be able to give informed consent. 
E 2.b The exclusion criteria are: 1) history of eating disorder, 2) weight loss (>5% body weight in prior 6 
months), 3) severe obesity (BMI>40kg/m2), 4) significant GI disease (liver function tests >1.5x normal, 
persistent diarrhea, celiac disease, cirrhosis, hepatitis B or C), or gall bladder disorder that might alter 
glucose or bile-acid metabolism, 5) pregnant or nursing mothers, 6) history of diabetes mellitus, 7) history 
of serious cardiovascular disease; MI, angina pectoris, heart failure, coronary artery disease, stroke, 
uncontrolled hypertension, clinically significant valvular disease, prior endocarditis, 8) history of or active 
substance abuse (esp. history of alcoholism), 9) dementia or any condition that would prevent voluntary 
informed consent or compliance with research protocol, 10) debilitating myopathy or neuropathy, 11) 
coagulopathy, 12) new serious systemic infection during the 12 weeks prior to enrollment, 13) subjects 
with known allergy to bile salts, 14) subjects receiving drugs that interfere with bile acid absorption of 
metabolism including  clofibrate, bile acid sequestrants (e.g. cholestyramine, welchol, ezetimibe) or 15) 
subjects whom the PI or investigative team do not believe are appropriate to include in the study 
Participants of childbearing potential and/or their partners must agree to use acceptable methods of birth 
control beginning at the pre-study visit and throughout the study. Acceptable methods of birth control 
include abstinence, depo-provera or norplant, or 2 of the following intrauterine device (IUD-with or without 
local hormone release), diaphragm, spermicides, cervical cap, contraceptive sponge, and /or condoms. 
 
Study subjects will be recruited from the resources listed below.  
Washington University ACTU: Dr. Presti provides clinical care at the ACTU. Since establishment in 1987, 
over 1700 enrolled in 263 clinical research projects at the ACTU.  Since 2001, the ACTU has consistently 
enrolled 300-500 patients per year in HIV/AIDS clinical studies. The PI has worked with the ACTU for 
>10 years.   
Vanderbilt Comprehensive Care Clinic and Vanderbilt Therapeutics Clinical Trial Unit (VTCRS): Drs 
Koethe and Hulgan provide care for HIV+ patients at the VUMS-ACTU. They have an excellent 
relationship with local ASOs. The PI has been working with Dr. Hulgan for the last 14 months to begin a 
collaborative relationship of screening patients at the VUMS-ACTU for this protocol. The research team 
at VUMS are famililar with all aspects of the study including adverse events (both actual and theoretical) 
and the current data. They are experts in the provision of clinical care of HIV+ patients and regularly 
perform metabolic studies within this population.  
AIDS Service Organizations (ASO): The ACTU has excellent relationships with ASO’s and acts as 
consultants to them on medical issues and provides speakers on a regular basis. The ACTU has a close 
collaboration with the St.Louis Effort for AIDS (EFA), the largest ASO in the St. Louis Metropolitan area 
and Blacks Assisting Blacks Against AIDS (BABAA) the major ASO working with African-American HIV-
infected persons.  
Community Advisory Board (CAB): The CAB consists of individuals from patient, health care and 
community constituencies serving the target population. Dr. Presti attends the monthly meetings, and 
presents current activities to seek input from CAB members about priorities for the community. 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
15 
 
St Louis HIV Primary Care Task Force: Dr. Presti is a member of the St Louis HIV Primary Care task 
Force; a group of physicians who meet regularly to discuss research studies. In combination they care 
for ~2000 patients with HIV in the St. Louis metropolitan area. Historically 30% of our subjects have been 
referred from this group.   
Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN trial): Dr. 
Presti is Director of the ‘SUN’ Study.  250 patients are enrolled in this five-year, CDC-funded, longitudinal 
cohort study to evaluate the metabolic effects of HAART. 53% percent are African American and 26% 
are women. Enrollment in SUN will facilitate co-enrollment in the current proposal. 
 
 
 
3. Screening studies (Performed at WUSTL and VUMS-ACTU) 
Medical examination. All subjects will be screened with a detailed history and physical examination, 
pregnancy test (if female) and CBC, lipid profile, liver panel and resting 12-lead electrocardiogram. CD4 
T-cell count, and plasma viral load. Oral glucose tolerance test.  After an overnight (12 h) fast, blood 
samples for plasma glucose, and insulin will be obtained immediately before and every 30 min for 2 h 
after ingesting a 75 g oral glucose load. The criteria of the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus (67) will be used to determine diabetes..Other than these screening 
procedures, all other components of the study are performed at WUSTL. 
 Eligible subjects from VUMS-ACTU who are consented and are eligible will be discussed by the research 
team at VUMS-ACTU and the study PI, Dr. Reeds. If the subject meets eligibility criteria transport will be 
arranged by WUSTL for the patient to undergo body composition, assessment of intramyocellular and 
intrahepatic TG content and the inpatient isotope-infusion protocols at WUSTL. After completion of 
baseline inpatient testing they will be kept overnight and transported back to Nashville the following day. 
All eligible subjects will undergo baseline testing within 3 months of screening. Subjects will have their 
study medication dispensed at WUSTL and both WUSTL and the VUMS-ACTU will have a staff member 
(Rebecca Basham, RN, not involved in data analysis) unblinded to group assignment for safety. Subjects 
enrolled at VUMS-ACTU will return to VUMS-ACTU every ~7 days for a pill count, vital signs, and to 
assess for any medication intolerance or other AEs.  
 
Body Composition and assessment of intramyocellular and intrahepatic TG content: Body composition 
will be measured within a week of the isotope infusion protocol.  Total body fat and fat-free mass will be 
determined by dual energy x-ray absorptiometry (DXA) (Hologic QDR 4500, Waltham, MA) (68).  
Abdominal (subcutaneous and intra-abdominal) adipose tissue mass will be quantified by magnetic 
resonance imaging (69, 70). Intrahepatic TG content will be determined by proton MRS (3T whole-body 
system; Magneton Vision Scanner; Siemens, Erlanger, Germany) as previously described (71). 
Cardiovascular structure (Performed at WUSTL) 
 
Cardiac echo and tissue Doppler imaging.  Comprehensive resting echocardiography will be 
used to assess cardiac structure and function.  This test is performed using a state-of-the-art 
ultrasound system (Vivid E9 Leadership or Vivid I Portable Cardiovascular Systems, GE 
Healthcare).  Echocardiographic characterization will include assessments of left ventricular 
(LV) mass, LV size, LV systolic function, and LV diastolic function. LV mass will be determined 
by two methods: the 2D-derived LV mass indexed to body surface area and the 2D-guided M-
mode-derived cubed method indexed to height2.7 (LVM/Ht2.7), which has been used extensively 
in clinical trials of hypertension (as recommended by the American Society of Echocardiography 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
16 
 
guidelines for clinical trials) and has been shown to be highly reliable and a robust phenotype in 
overweight/obese populations 71-73.  The presence of LVH will be defined as an LVM/Ht2.7 
greater than two standard deviations above the mean (i.e. >47 g/m2.7 for men, >44 g/m2.7 for 
women) 74.  2D-directed echocardiographic measurements include the LV end-diastolic and 
end-systolic volumes using the method of discs. The LV ejection fraction (LVEF) will be 
calculated using the modified Simpson’s method (LVEF ≥55% considered normal).  LVDD will 
be characterized as follows: 1) PWD-derived transmitral indices recorded from the four-chamber 
view at the mitral valve leaflet tips, including the early diastolic (E-wave) and atrial (A-wave) 
velocities, E/A velocity ratio, E-wave deceleration time (DT), and the isovolumic relaxation time 
(IVRT) 75; 2) Tissue Doppler Imaging (TDI)-derived early diastolic myocardial velocity (E’) 
obtained at the septal and lateral mitral annulus from the apical four-chamber view and the 
averaged value 75-77.  TDI-derived indices of LV diastolic relaxation (i.e., E’ velocity) are 
relatively load-independent and inversely correlate with the degree of interstitial fibrosis 78-81. 
Consistent with the recommendations of the American Society of Echocardiography for clinical 
studies of patients with hypertension, TDI-derived early diastolic mitral annular velocity (E’) will 
be used as the primary assessment of diastolic function 73.  When dichotomization of LVDD is 
necessary for analysis, an E’ <9.0 cm/s will be considered evidence of impaired LV relaxation.  
Measurements will be reported as the average of values from 3 consecutive cardiac cycles. 
 
5. Isotope-Infusion Protocols.  
Pre-study dietary intake and physical activity. All subjects will be instructed to abstain from any exercise 
and to ingest a standard weight-maintaining diet for three days before the isotope infusion protocol. Our 
study dietician will give dietary instructions individually to each subject. Each subject will keep a complete 
3-day food log to judge compliance. The diet will contain at least 300 g of carbohydrate/day and the 
relative contributions from protein, carbohydrate, and fat will be approximately 15%, 55%, and 35% of 
calories, respectively. On the third day of the diet, subjects will be admitted to the IRU at 1600 h and their 
3-day diet records will be reviewed.  If their diet is inappropriate (e.g. inadequate in carbohydrate or 
energy intake) the study will be rescheduled. The study’s dietary counselor will provide counseling by 
phone to participants recruited from the Vanderbilt site. 
Hyperinsulinemic euglycemic clamp. Subjects will be admitted to the Clinical Research Unit (CRU) for 
isotope infusion studies to assess insulin sensitivity in liver, adipose tissue and skeletal muscle (Fig 12).    
At 1800 h on the day of admission, subjects will be given a standard meal (containing 15 kcal/kg FFM), 
which will be consumed by 1900 h.  Subjects will then receive a can of BoostTM. After this meal, subjects 
will fast until completion of the isotope infusion studies the following day.  At 0500h, a catheter will be 
inserted into the antecubital vein of the arm to infuse isotope tracers and another catheter will be placed 
in the contralateral dorsal hand vein. The hand will then be placed in a thermostatically controlled box 
heated to 55C to obtain arterialized blood samples. If a hand vein cannot be cannulated, a radial arterial 
line will be placed.  We have found that a radial artery catheter is well tolerated by study subjects, and 
ensures rapid and secure blood sampling.  We now have inserted hundreds of catheters without any 
complications. 
 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
17 
 
At 0600 h a hyperinsulinemic-euglycemic clamp procedure with isotope infusion will be initiated to 
determine hepatic (glucose production), skeletal muscle (glucose disposal) and adipose tissue (lipolysis) 
insulin sensitivity.  After baseline blood samples are obtained, [6,6-2H2]glucose (22 µmol/kg prime and 
0.22 µmol.kg-1.min-1 constant infusion) will be infused.  After 90 min (0730 h), a constant infusion of [U-
13C]palmitate (6 nmol.kg FFM-1.min-1) will be started to determine the rate of appearance (Ra) of plasma 
palmitate .  At, 0930 h, after the basal period is completed, a two-stage euglycemic, hyperinsulinemic 
clamp will be initiated and continued for 6.5 h. Euglycemia will be achieved by a variable rate infusion of 
20% dextrose enriched to approximately 2.5% with [6,6-2H2]glucose to minimize changes in glucose 
isotopic enrichment.  Adding tracer to the dextrose infusion has been shown to provide more accurate 
measures of glucose Ra (72), by minimizing changes in plasma glucose enrichment.  During stage 1 of 
the clamp (3.5 h to 6.5 h of isotope infusion), insulin will be infused at a rate of 7 mU.m2.min-1 for 3 h 
(initiated with a two-step priming dose of 30 mU.m2.min-1 for 5 min followed by 15 mU.m2.min-1 for 5 min), 
which will achieve plasma insulin concentrations of ~25 µU/ml. During stage 2 of the clamp (6.5 h to 10 
h of the isotope infusion), insulin will be infused at a rate of 50 mU.m2.min-1 for 3.5 h (initiated with a two-
step priming dose of 200 mU.m2.min-1 for 5 min followed by 100 mU.m2.min-1 for 5 min), which will achieve 
plasma insulin concentrations of approximately 80 µU/ml. These plasma insulin concentrations provide 
an optimal range for evaluating insulin’s effect on hepatic glucose production and lipolysis (low-dose 
insulin infusion) and glucose uptake by skeletal muscle (high-dose insulin infusion).  The infusion of 
[2H2]glucose and [U-13C]palmitate will be decreased by 50% of basal during stage 1 and by 75% during 
stage 2 because of the expected decreases in hepatic glucose production and lipolytic rate. Plasma 
samples will be taken before beginning the infusion to obtain baseline measurements of substrate 
enrichment. Plasma samples will be taken every 10 min during the last 30 min of the basal period and 
 
 
0
1
2
3
4
5
6
7
7.5
 
Insulin
Basal 
Stage 1 
 
IVGTT 
 
Variable 20% Dextrose  
with 2.5% [
2H2] glucose  
 
[U-
13C] palmitate 
 
[
2H2] glucose 
 50 mU•m
-2•min
-1 
 
Biopsy 
Time (h) 
Blood samples 
Fig 12. Schematic diagram of isotope infusion protocol. IVGTT (intravenous glucose tolerance test) 
blood draws every 2 minutes for 8 minutes.  


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
18 
 
each stage of the insulin clamp to determine glucose and FFA concentrations and kinetics, and insulin 
concentrations. Plasma samples will be obtained every 10 min at the end of the basal period and 
throughout the entire clamp to monitor plasma glucose concentration.  
At the completion of the clamp, the insulin  will be turned off . Plasma glucose will be checked every 10 
minutes and the rate of 20% dextrose infusion will be reduced by 50% if BG >100mg/ml. After the 20% 
dextrose is off PG is checked every 10 min until BG returns to baseline. A bolus of 0.3g/kg of dextrose 
will then be given intravenously over one minutes. Bloo samples will be taken every 2 minutes for 8 
minutes total to measure plasma insulin and c-peptide concentrations. In the event of hypoglycemia 
during the clamp (BG<60mg/dl) the insulin will be turned off, 20 grams of glucose will be given 
intravenously and the D20 rate will be titrated to achieve BG>100mg/dl. The study will then be aborted 
and the subject will be fed and observed as described above.  
Oxygen consumption and carbon dioxide production will be measured by indirect calorimetry at 0900, 
1200 and at 1600 h, for 30 minutes by using a metabolic cart and a ventilated hood system (Parvomedics 
TrueOne2400, Parvomedics, Sandy, UT).  These data will be used to examine energy expenditure and 
substrate oxidation. 
Tissue Biopsy: Tissue will be obtained from subcutaneous abdominal adipose tissue and the vastus 
lateralis muscle 60 min after starting the glucose tracer infusion (basal stage of the clamp procedure).  
Muscle and fat biopsies will also be obtained 60 min after starting stage 2 of the clamp procedure to 
determine the effect of insulin infusion on insulin signaling and adipocyte markers.  The biopsy sites will 
be cleaned and draped in a sterile manner. After anesthetizing the area with lidocaine, adipose tissue 
will obtained aspirated through a liposuction cannula, ~200 mg of muscle will be obtained by using a 6 
mm Bergstrom needle inserted through a small (0.5 cm) skin incision. All tissue samples will be 
immediately rinsed with ice-cold saline.  Adipose tissue samples will be divided into 2 aliquots: 1) 
immediately frozen in liquid nitrogen for subsequent determination of cell factors and quantitative PCR 
2) ) placed in formalin for subsequent microscopy and immunohistochemistry analyses The PI has 
performed several hundred of these procedures and they are well tolerated by subjects. 
 Analysis of Samples.  All analytical procedures required for this proposal are routinely performed in Dr. 
Klein’s, Dr. Finck’s, and Dr. Abumrad’s laboratories, the CRU Core Laboratory, the Nutrition and Obesity 
Research Core (NORC) and the Adipocyte Core Biology Laboratories. Screening laboratory specimens 
obtained from participants who complete the screening visit at the Vanderbilt site will be processed by 
LabCorp using commercially available assays (Birmingham, AL)”. 
Plasma glucose and palmitate, kinetics:  The resources of the NORC will be used for sample analysis. 
The lab has streamlined methods to process plasma to recover these substrates and derivatize them for 
GC/MS analyses (69, 70, 73-75). Steele’s steady state equation(76) will be used to calculate substrate 
kinetics. 
Molecular correlates of insulin sensitivity: We have hypothesized that TUDCA administration will 
improve insulin sensitivity in HIV+ subjects receiving ART. To evaluate molecular indicators of this, the 
phosphorylation status of several proteins that are downstream of the insulin receptor signaling cascade 
will be assessed, including phosphoserine473 and total Akt/protein kinase B (PKB) and total, 
phosphotyrosine, and phosphoserine IRS-1 by immunoblotting. These endpoints will be assessed during 
baseline conditions and during stage 2 of the clamp in skeletal muscle biopsies and quantified as 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
19 
 
described just above. Briefly, total cellular proteins will be extracted by mechanical disruption using a 
Tissue-Lyzer in lysis buffer containing protease and phosphatase inhibitors. Protein concentration will be 
determined and proteins electrophoresed under denaturing conditions. Western blot results will be 
visualized and band intensity quantified using the Licor Odyssey system provided by the NORC. The 
intensity of the phosphorylated forms of the proteins are corrected for total content of that protein and 
normalized to the baseline value. Dr. Finck’s laboratory performs these analyses routinely (77-80) 
including in the prior TUDCA study (43).  
Measurement of serum bile acid concentration: Plasma bile acids will be measured using high-
performance liquid chromatography tandem mass spectrometry (81) 
Other assays: Plasma insulin, CRP, adiponectin, leptin, TNF α and IL-6 will be measured by the CRU 
Core laboratory using commercially available assays (Linco, St Charles, MO). 
Specific Aim 2: Determine the effect of TUDCA on markers of TGR5 activation.  
A major strength of this proposal is the systematic and rigorous examination of the molecular 
mechanisms that are likely to be responsible for the metabolic effects of TUDCA. Our leading hypothesis 
is that TUDCA enhances insulin sensitivity in skeletal muscle by activating the G-protein coupled cell 
surface receptor TGR5. This hypothesis will be tested by examining the mRNA expression and protein 
abundance of TGR5 targets in subjects before and after treatment with TUDCA (or placebo). We will 
then determine the requirement for TGR5 signaling for the response to TUDCA by using siRNA-based 
TGR5 silencing.  
In vivo studies: We will evaluate markers of TGR5 activation (PGC-1, several genes encoding fatty acid 
oxidation enzymes, enzymes involved in electron transport, and type 2 deiodinase) in adipose and 
skeletal muscle tissue samples taken before and after administration of TUDCA at the levels of protein 
abundance and mRNA expression. Protein will be isolated in the presence of protease and phosphatase 
inhibitors as described in Aim 1. The protein content and/or phosphorylation status will be performed by 
using western blotting. The antibodies above are all commercially available and have been used 
previously by Dr. Finck’s lab (43, 74, 77-80, 82-84). Total RNA will be isolated from tissue biopsies using 
RNAzol Bee as we have described numerous times previously (43, 74, 77-80, 82-84). Quantitative RT-
PCR will be performed by using reagents from Applied Biosystems and the ABI 7500 provided by the 
NORC Adipocyte Biology Core. Muscle mitochondrial DNA content will also be determined by back-
extracting total DNA during RNA extraction and measuring the DNA for the mitochondrial gene, Cox1, 
and normalizing to nuclear DNA content by measuring RPLP0 DNA, which is encoded in the nucleus. 
Primer sets have been validated to specifically detect mRNAs of interest. We predict that TUDCA 
treatment will lead to increased expression and protein abundance of markers of TGR5 activation in 
human skeletal muscle. 
In vitro studies: If our preliminary data hold true and the analyses described just above show that TUDCA 
administration activates multiple markers of TGR5 activation, cell biological approaches will be used to 
determine whether TGR5 is required for the ameliorative effects of TUDCA on insulin signaling and 
glucose uptake. Human skeletal satellite cells will be isolated and differentiated into myocytes in culture 
as described in the preliminary data. TGR5, which is well expressed in skeletal muscle cells (44), will 
then be knocked down by using siRNAs purchased from Sigma. We do not consider this to be a significant 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
20 
 
technical hurdle as this technique is used frequently and successfully by Dr. Finck and Dr. Chen (78, 82-
86) and Sigma will continue to provide oligonucleotide siRNA candidates until successful knockdown is 
achieved. After identifying efficient siRNAs to knockdown TGR5, differentiated myocytes will be treated 
with siRNAs to TGR5 (or scrambled siRNA control) for 72 h, myocytes will be treated with RTV (or vehicle) 
with or without pre-treatment with TUDCA as described in preliminary studies. Endpoints will include 
assessment of protein and mRNA markers of TGR5 activation and ER stress. Subsequent studies will 
include insulin stimulation to assess phosphorylation of insulin signaling cascade proteins and uptake of 
2-deoxyglucose (as described in preliminary studies). We predict that knockdown of TGR5 will abolish 
the activation of D2 and other proteins under the control of this signaling pathway. In addition, if TGR5 
activation is important to the insulin-sensitizing effects of TUDCA, loss of TGR5 may also attenuate the 
ability of TUDCA to increase insulin sensitivity in these skeletal myotubes. 
Specific Aim 3 Determine the effect of TUDCA on ER stress.  
Alternatively or in addition, we have hypothesized that TUDCA may improve insulin signaling by reducing 
ER stress, possibly in a cell type-specific manner. To test this hypothesis, we will evaluate markers of 
ER stress in tissue biopsy samples taken before and after administration of TUDCA. We will also evaluate 
the direct effects of TUDCA and RTV on these endpoints in adipocytes in culture to begin to dissect the 
molecular mechanisms involved.  
The proposed methods will examine all three major pathways of the UPR; specifically we will assess 1) 
activation of PERK by measuring protein abundance of PERK, pEIF2a, EIF2a, and ATF4, 2) ATF6 
activation by measuring the protein abundance of ATF6 and 3) Xbp1 splicing by measuring spliced Xbp1 
content. We will also assess downstream targets of these pathways by measuring protein content of 
BIP/Grp78 and activation of the JNK pro-inflammatory pathway by measuring phosphoJNK.  
In vivo studies: ER stress markers will be quantified in adipose tissue and skeletal muscle of study 
subjects. Protein and RNA will be isolated as described above and markers evaluated by using western 
blotting and qRT-PCR. We will assess various markers by protein abundance or phosphorylation status 
(BIP/Grp78, Grp94, pEIF2a/EIF2a, IRE-1, PERK, spliced Xbp1, Chop, ATF6, ATF4, and phosphoJNK).  
The splicing of Xbp1, which is increased by ER stress will be assessed by using SYBR chemistry 
quantitative reverse transcriptase-PCR (Applied Biosystems).  Relative abundance calculated using the 
delta-Ct method (2-ΔCt) with a housekeeping gene (RPLP0). Total RNA will be extracted from frozen 
muscle and adipose biopsy samples as described (87). Adipose tissue samples taken before and after 
the intervention will be analyzed for macrophage and inflammatory gene expression (IL-6 and TNF-α 
expression, F4/80, CD68, EMR1,CD11b, MIP-1a, CCL3-R) to determine if administration of TUDCA 
affects markers of adipose tissue inflammation. We predict that treatment with TUDCA will reduce signs 
of ER stress in adipose tissue, but not skeletal muscle, of study subjects treated with PI-ART. 
In vitro studies: If, as predicted, TUDCA reduces ER stress in adipose tissue above, the effects could be 
direct effects of TUDCA as a chemical chaperone in adipocytes or could be secondary to systemic 
improvements in insulin sensitivity and metabolism. To address this issue, the human adipocyte cell line 
(Lisa-2; provided by the NORC ABC) will be cultured and differentiated in vitro. Adipocytes will then be 
treated with RTV and/or TUDCA as described for the human skeletal myocytes in prelim studies. 
Endpoints will include markers of ER stress, insulin signaling, and 2-DG uptake. Based on preliminary 
studies and published work showing that PI-ART activates ER stress in adipocytes (19, 88, 89) we predict 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
21 
 
that treatment of adipocytes with RTV will activate the ER stress response and impair insulin signaling 
and glucose uptake and that TUDCA will attenuate or reverse these effects of RTV.  
Finally, it is also possible that the ability of TUDCA to ameliorate ER stress could be blocked by loss of 
TGR5 signaling. Though this would seem to be a more unlikely possibility, the mechanism whereby 
TUDCA ameliorates ER stress is not known, and could involve TGR5 signaling. To test this ideas, TGR5 
will be knocked down by using siRNA (as described for myocytes) and the ability of TUDCA to ameliorate 
ER stress and improve insulin responsiveness in adipocytes will be examined. These mechanistic studies 
would provide a significant conceptual advance for the field by establishing the mechanism whereby 
these effects occur.    
E 2.C  
Randomization. Participants will be randomized to TUDCA or placebo. A computer-based randomization 
scheme will be established, as used in our prior research protocols (90) and group assignment will be 
stratified by race and gender. The study statistician, Dr. Schechtman, who will be unblinded to group 
assignment, will provide ongoing oversight to ensure groups are well matched on key characteristics 
(age, BMI, race, gender). Capsules containing TUDCA and matching placebo will be made by our 
research pharmacy, as has been performed in our other placebo-controlled studies (90). The PI, subjects 
and research technicians will be blinded with respect to group assignment. The coordinator will also be 
unblinded to group assignment. In the event of an adverse event the coordinator will inform the team and 
subject of group assignment. Melisa Moore RN and Rebecca Basham RN will be unblinded to ensure 
that group assignment is known in the case a subject requires urgent medical care. 
Sample Size and statistical power: All power computations are based on two-sided tests at the 0.05 
level of significance for the primary outcomes of change of 1) insulin-stimulated glucose disposal (SA#1), 
2) type 2 deiodinase expression in skeletal muscle (SA#2) and 3) Grp78 expression in adipose tissue 
(SA#3) after the intervention.  
Significance of primary outcomes: Change in insulin-stimulated glucose disappearance is clinically 
relevant as a predictor of diabetes risk and is highly reproducible in our hands, improving statistical power 
(91). D2 and Grp78 expression are robust markers of TGR5 activation and ER stress, respectively, and 
will therefore clarify the mechanisms through which TUDCA may act to improve insulin sensitivity.  
Estimates of change in the primary outcomes: The estimates for the anticipated changes in the primary 
endpoints of glucose disposal and D2 expression are based on the prior study conducted in obese, insulin 
resistant subjects. In this study, glucose rate of disappearance improved by 30±23% and D2 expression 
in muscle increased 2.4±2.5 fold (Fig 10) after the TUDCA intervention (43). The estimate for the change 
in Grp78 expression following initiation of TUDCA is based on improvements seen in animal studies with 
use of TUDCA (52, 53) and in humans after undergoing gastric bypass (92). Based on these findings we 
estimate a 50±25% change in Grp78 in the TUDCA group with no change in the placebo group.  
G  
G1. Statistical analysis:  Preliminary analyses will include analysis of variance and chi square tests that 
focus on ensuring that the groups are similar at baseline.  The primary analytic approach will be analysis 
of covariance in which the dependent variable will be the post intervention value of the outcome measure 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
22 
 
and the independent variables will be the study group and the baseline value of the outcome.  This will 
allow us to test hypotheses about the equality of post intervention values after adjusting for the baseline 
value.  In these analyses, we will be specifically interested in the statistical contrasts that compare the 
groups with and without TUDCA.  The appropriateness of all analysis of variance and covariance models 
will be evaluated using regression residuals.  If normality or homoscedasticity requirements are violated, 
data transformations will be explored and, if appropriate transformations cannot be found, analyses may 
be done semi-parametrically using the ranks of the data.  
G2. Power Estimates for each primary endpoint: We have conservatively estimated the improvements 
in our primary endpoints. We plan to include 24 subjects in each group and conservatively estimate a 
33% drop-out rate. These drop-out rates are greater than those seen in our prior studies in HIV+ people 
using longer duration interventions that have high drop-out rates such as exercise (10% drop-out) or yoga 
(15% drop-out) (32, 93).  
The above data have the following implications with respect to statistical power (see Table).  The 
anticipated treatment induced improvement in the glucose disappearance rate of 30 + 23% implies that 
a sample size of only 16 yields a power of 0.95 (SA#1).  The expectation that TUDCA will increase D2 
expression in muscle by 2.4 + 2.5 yields a power of 0.85 with 16 subjects per group (SA#2).  Finally  the 
expected change of 50 + 25% in Grp78 in the TUDCA group implies that only 7 subjects per group are 
needed to achieve a power of 0.93 (SA#3). In summary, our sample size selection implies that the power 
associated with the glucose disappearance rate (SA#1) and Grp78 (SA#3) will exceed 0.9 while the 
power associated with D2 expression will be 0.85.  
 
G3. Statistical power estimates 
 
 
 
Study Timetable: 
Variable 
HIV+ Placebo 
HIV+ TUDCA 
Power for detecting differences 
between groups after 
intervention (30% dropout) 
Improvement in insulin-stimulated 
glucose disposal (%) 
0±20 
30±23 
0.95 (if N=16 per group) 
Fold-change in D2 expression after 
intervention 
0±1.8 
2.4±2.5 
0.85 (if N=16 per group) 
Fold-change in Grp 78 expression 
after intervention 
0±0.25 
-0.50±0.25 
0.97 ( if N=16 per group) 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
23 
 
 
Subjects 
Year 1 
8 
Year 2 
12 
Year 3 
12 
Year 4 
12 
Year 5 
4 
Total studies 
48 
 
 
H. Protection of human subjects. 
H1. Risk to subjects.   Blood and tissue samples will be collected from all subjects.  The specimens will 
be obtained solely for research purposes.  Study samples and data sheets will be coded with an 
identification number for each subject.  All of the data from individual subjects will be maintained 
confidentially and their names and identities will not be disclosed in any published document. The PI, 
coordinator and Dr. Presti are covered by a certificate of confidentially carried by the ACTU. 
Potential risks of the study include: 1) the risks of catheter insertion and blood drawing include discomfort, 
bleeding or infection at the site of insertion; 2) the infusion of hormones may cause changes in blood 
glucose and may cause nausea, however, blood glucose is monitored throughout the study; 3) biopsies 
of muscle and adipose tissue can cause pain, bleeding, and infection; 4) magnetic resonance 
spectroscopy  and MRI can be harmful for people with metal implants in their bodies, and may cause 
discomfort in people with claustrophobia; (those with implants or history of claustrophobia will be 
excluded); 5) if an arterial line is placed, a blood clot can occur at the site of the catheter insertion and 
could decrease blood flow to the hand causing tissue damage (however, the risk of this is extremely small 
because only a small size catheter is used and it is kept in for a short period of time; furthermore, before 
catheter placement, the hand is examined to ensure adequate blood flow); 6) the risks of infusing stable 
isotope tracers include the possibility of pyrogen response or infection; however, all solutions will be 
tested for pyrogens and sterility before infusion and will be administered under strict aseptic conditions; 
there are no known short- or long-term risks associated with the infusion of the isotopes themselves; 7) 
the effect of TUDCA on ART absorption and handling is not known therefore we will enrol only subjects 
with controlled HIV and will monitor CD4 counts and viral load upon completion of this brief study. These 
results will be reviewed by the DSMB to ensure patient safety.   
Adequacy of protection against risks.  All experimental procedures will be explained in writing and orally 
to the subject by the principal investigator, co-investigator, or the research coordinator. Written informed 
consent will be obtained after all questions have been answered and the risks and benefits of participation 
in the study have been described. The objectives of the project, all of the requirements for participation, 
and any possible discomforts and risks will be clearly explained to each subject orally and in writing in 
lay terms that he/she is able to comprehend. The subject must sign a consent form, approved by the 
Washington University School of Medicine Institutional Review Board, before participating in any aspect 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
24 
 
of the study.  To secure data transfer between WUMS and VUMS, a Secure File Transfer system will be 
used to transmit any PHI or study-related data. An original copy of each consent will be kept on file at the 
primary site with an additional signed consent at VUMS. At each site all data will be kept within a secure 
server and will be deidentified at the closure of the study.  
H2 Compliance Program: During the intervention, subjects will be seen weekly by a member of the 
research team who will take weight, measure blood pressure and pulse, review any problems and verify 
compliance by using a pill count. Should the need for medical evaluation arise, they will be seen by the 
PI,Dr. Presti, Dr Hulgan, Dr. Koethe all of whom are certified in Internal Medicine.  
 
Should the need for medical attention arise all the resources of a large teaching hospital at each 
site are available for subject evaluation and treatment. Complete physical examinations will be performed 
to screen out subjects who may be at potential risk.  Subjects will be carefully monitored by the medical 
staff associated with the study for the duration of the study. 
Potential benefits of the proposed research to the subjects and others.   Potential benefits to the subjects 
participating in the study include information regarding their medical health, and screening for diabetes.  
Benefits to society include a better understanding of the factors responsible for insulin resistance in HIV 
and the mechanisms through which bile acids may improve these outcomes.  
Importance of the knowledge to be gained. This study will provide important information regarding the 
causes of insulin resistance in HIV and will test the efficacy of a new modality. The risks associated with 
this research are minimal relative to the clinical implications of this study, which could lead to better 
therapies for preventing and treating the metabolic complications of PI-ART. 
H3 Data and safety monitoring. Data from the study will be monitored on a continuous basis by the PI, 
co-investigators, study research nurse, and research coordinator.  The PI, study research nurse, research 
coordinator, and postdoctoral research fellow will meet weekly to review any study issues. The PI, study 
research nurse, and research coordinator will review all serious adverse events (SAEs), adverse events 
(AEs), and laboratory values.  Dr. Hulgan, the study research nurse and coordinator at VUMS will also 
discuss weekly eligible or enrolled subjects. In the event of an SAE or reportable event, Dr Hulgan or 
Koethe will contact Dr. Reeds within 24 hours. The Washington University Human Research Protection 
Office (HRPO) will be notified as a reportable event within 10 days of knowledge of the event.  Follow-up 
will be performed as additional information becomes available.  In addition, all laboratory values outside 
of normal range which place the participant at risk are discussed with the study participant and 
appropriate arrangements will be made for treatment, if necessary.  Data from the study will be monitored 
on a continuous basis by the PI, co-investigators, research coordinator, and research study nurse.  
A Data and Safety Monitoring Board, consisting of Shelby Sullivan, M.D. (Gastroenterologist), David 
Alpers. (Gastroenterologist), and David Clifford, M.D. (Infectious Diseases), will be available for 
discussion at any time with the PI to review any safety issues. All data will be treated confidentially and 
the subjects' names and identities will not be disclosed in any published reports. The subjects will be 
informed orally and in writing that they are free to withdraw from the study at any time with no bias or 
prejudice. The data obtained from this study will be kept confidential and no subjects will be identified in 
any written publications. Patients are assigned a study specific identifying number upon entry to the 
study, after which all medical information is referenced by this number.  Clinic records are maintained in 
locked file cabinets within a locked room. 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
25 
 
 
 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
26 
 
Appendix 1.  
Animal Toxicity Studies (supplied by Bruschettini S.r.l.) 
 
 
 
Name of company: BRUSCHETTINI S.r.l. 
TABULATED 
  
  
  
  
  
Name of finished product: TAUROLITE 
STUDY REPORT 
  
  
Name of active ingredient:  
Ref. Part III B - Vol. 10 
  
  
Tauroursodeoxycholic acid 
  
  
  
  
  
  
  
  
REPEATED DOSE TOXICITY: (sub chronic toxicity) 
  
  
  
  
  
  
Ref. to document: prof. M. De Bernardi - University of Pavia - II Chair of Toxichology 
  
  
  
Bibliographic ref. (...): 
  
  
  
  
  
  
  
  
Species: Dog / Beagle 
  
  
  
Number of animals: 18 (9 M + 9 F) 
Administration route: i.p. saline solution 
  
  
Test article: TUDCA 
  
  
Study group 
1 
  
2 
  
3 
  
  
  
Number of test animals 
    3 M + 3 F 
    3 M + 3 F 
    3 M + 
3 F 
  
  
  
Dosage and frequency (mg/kg/day) 
Saline 
solution 
 50 mg/kg/day 
150 mg/kg/day 
  
  
Duration of treatment (weeks) 
4 
  
4 
  
4 
  
  
  
TESTS 
  
  
  
  
  
  
  
  
Animal behaviour 
  
Blood chemistry: erythrocytes, heamoglobin, haematocrit, leucocytes with formula 
  
Biochemical: glycemia, azotemia, creatininemia, cholesterolemia, serum electrolytes (Na, K, Ca), 
  
bilirubine, protidemia, serum-electrophoresis, SGOT, SGPT, ALP 
  
Urine tests: measurement of volume in 24 hours, specific weight, protein, glucose, ketonic bodies, 
  
bilirubin, blood microscopic sediment test. 
  
Macroscopic test and weight of organs: liver, kdneys, spleen, surrenals, testicles, ovaries, heart, brain,  
pituitary gland, thymus and lungs 
  
Histology: lilver, kidneys, spleen, surrenals, testicles, ovaries, uterus, heart, brain, pituitary glands 
  
lungs, stomach, small intestine, colon, pancreas, bladder, thyroid, eye 
  
  
  
  
  
  
  
  
  
  
FINDINGS 
  
Biochemical and blood chemistry: 50 mg/kg/day - No pathological modification of the various para- 
  
meters. 150 mg/kg/day - No pathological modification of the various parameters 
  
Behaviour - Macroscopic test - histology: 50 mg/kg/day - No behavioral, macroscopic, nor histological  
modification; 150 mg/kg/day - No behavioral, macroscopic, nor histological modification 
  


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
27 
 
 
Name of company: BRUSCHETTINI S.r.l. 
TABULATED 
  
  
  
  
  
Name of finished product: 
TAUROLITE 
  
STUDY REPORT 
  
  
  
Name of active ingredient: 
  
Ref. to Part III B 
  
  
  
Tauroursodeoxycholic acid 
  
Vol. 10 
  
  
  
  
  
  
REPEATED DOSE TOXICITY (chronic toxicity): 
  
Ref. to document: Prof. M. De 
Bernardi 
  
Bibliographic ref. (...): 
  
  
  
  
  
  
  
  
Species: Rat / Sprague Dawley 
  
  
  
Number of animals: 
80 (40 M + 40 F) 
Administration route: per os 
  
  
  
Test article: TUDCA 
  
  
Formulation of test substance and concentration: suspension in arabic gum 10% solution 
  
  
Study group 
1 
  
2   
3 
  
4 
  
  
  
  
  
  
  
  
  
  
Number of test animals 
10 M 
10 F 
10 M 
10 F 
10 M 
10 F 
10 M 
10 F 
Dosage and frequency (mg/kg/day) 
arabic 
gum  
placebo 
300 
mg/kg/day 
  
600 
mg/kg/day 
  
1200 
mg/kg/day 
  
Duration of treatment (weeks) 
26 
26 
26 
26 
26 
26 
26 
26 
TESTS 
  
  
  
  
  
  
  
  
Behaviour and body weight 
  
Blood chemistry: erythrocytes, haemoglobin, haematocrit, leucocytes with formula 
  
Biochemical: glycemia, azotemia, creatininemia, cholesterolemia, serum electrolytes (Na, K, Ca), 
  
bilirubinemia, protidemia sero-protein electrophoresis, SGOT, SGPT 
  
Urine tests: measurement of volume in 24 hours, specific weight, pH, protein, glucose, ketonic bodies,  
bilirubin, blood, microscopic sediment test 
  
Macroscopic test and weight of organs: liver, kidneys, spleen, surrenals, testicles, ovaries, uterus, heart, 
pituitary gland, thymus and lungs 
  
Histology: liver, kidneys, spleen, surrenals, testicles, ovaries, uterus, heart, brain, pituitary gland, thymus, 
lungs, stomach, small intestine, colon, pancreas, bladder, prostate, thyroid, eye 
  
  
  
FINDINGS 
  
  
  
  
  
  
  
  
Biochemical and blood chemistry:  
  
300 mg/kg/day no pathological modification of the various parameters; 
  
600 mg/kg/day no pathological modification of the various parameters 
  
1200 mg/kg/day no pathological modification of the various parameters 
  
Behaviour - Macroscopic test - Histology 
  
300 mg/kg/day  no behavioural, macroscopic nor histological modification 
  
600 mg/kg/day  no behavioural, macroscopic nor histological modification 
  
1200 mg/kg/day  no behavioural, macroscopic nor histological modification 
  
 
 
 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
28 
 
Name of company: BRUSCHETTINI S.r.l. 
TABULATED 
  
  
  
  
  
Name of finished product: 
TAUROLITE 
STUDY REPORT 
  
  
Name of active ingredient:  
Ref. to Part III B 
  
  
Tauroursodeoxycholic acid 
  
Vol. 
12 
  
  
  
  
  
  
REPEATED DOSE TOXICITY (chronic toxicity): 
  
  
  
  
  
  
  
Ref. to document: Prof. F.A. Bertè 
  
  
  
  
  
  
  
  
Bibliographic ref. (...): 
  
  
  
  
  
  
  
  
Species: rat / Winstar 
  
  
  
Number of animals: 
80 (40 M + 40 F) 
Administration route: p.o. suspension in gum arabic 10% 
  
Test article: 
TUDCA 
  
  
Study group 
1   
2 
  
3   
4 
  
Sex (m/f) 
m 
f 
m 
f 
m 
f 
m 
f 
Number of test animals 
10 
10 
10 
10 
10 
10 
10 
10 
Dosage and frequency (mg/kg/day) 
          
placebo 
  
250 
mg/kg/day 
  
500 
mg/kg/day 
  
1000 
mg/kg/day 
  
Duration of treatment (weeks) 
26 
26 
26 
26 
26 
26 
26 
26 
TESTS 
  
  
  
  
  
  
  
  
Mortality, behaviour, body weight, water and food consumption 
  
Blood chemistry: erythrocytes, haemoglobin, haematocrit, leucocytes with formula 
  
Biochemical: glycemia, azotemia, protidemia, cholesterolemia, serum electrolytes (Na, K, Ca),  
  
bilirubinemia, SGOT, SGPT, ALP 
  
Urine tests: protein, glucose, ketonic bodies, bilirubin, blood 
  
Weight of organs: brain, thyroid, heart, liver, kidneys, spleen, testicles, ovaries 
  
Macroscopic test and histological tests: brain, heart, thyroid, liver, lungs, kidneys, spleen, surrenals,   
testicles, ovaries, lymphatic ganglions, salivary glands, mammary glands, pituitary gland, thymus, 
  
pancreas, bladder, prostate, uterus, eyes, spinal marrow, gastroenteric apparatus (trachea, oesophagus,  
stomach, small intestine, colon, ribs, femurs, vertebrae (including bone marrow) 
  
  
  
FINDINGS 
  
Biochemical and blood chemistry:  
  
250 mg/kg/day no pathological modification of the various parameters; 
  
500 mg/kg/day no pathological modification of the various parameters 
  
1000 mg/kg/day no pathological modification of the various parameters 
  
Behaviour - Macroscopic test - Histology 
  
250 mg/kg/day  no behavioural, macroscopic nor histological modification 
  
500 mg/kg/day  no behavioural, macroscopic nor histological modification 
  
1000 mg/kg/day  no behavioural, macroscopic nor histological modification 
  
 
 
 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
29 
 
References 
1. 
Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy 
and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch 
Intern Med. 2005;165(10):1179-84. 
2. 
Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, et al. Ten-
year diabetes incidence in 1,046 HIV-infected patients started on a combination antiretroviral 
treatment: the ANRS CO8 APROCO-COPILOTE cohort. AIDS (London, England). 
3. 
Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, et al. Diabetes mellitus, 
preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in 
patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of 
Anti-HIV Drugs (D:A:D Study). Circulation. 2009;119(6):805-11. PMCID: 2715841. 
4. 
Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. 
Combination antiretroviral therapy and the risk of myocardial infarction. The New England journal 
of medicine. 2003;349(21):1993-2003. 
5. 
Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, et al. 
Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV 
infection. AIDS (London, England).24(10):1509-17. PMCID: 2884071. 
6. 
Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting 
hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-
infected women. The Journal of clinical endocrinology and metabolism. 1999;84(6):1932-7. 
7. 
Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of 
antiretroviral drugs and the risk of myocardial infarction. The New England journal of medicine. 
2007;356(17):1723-35. 
8. 
Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors 
associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss 
HIV Cohort Study. Clin Infect Dis. 2007;45(1):111-9. 
9. 
Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. 
HIV infection and the risk of diabetes mellitus. AIDS (London, England). 2009;23(10):1227-34. 
PMCID: 2752953. 
10. 
Hruz PW, Yan Q, Struthers H, Jay PY. HIV protease inhibitors that block GLUT4 
precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. 
Faseb J. 2008;22(7):2161-7. 
11. 
Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV 
protease inhibitor therapy. J Biol Chem. 2000;275(27):20251-4. 
12. 
Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW. HIV protease inhibitors acutely 
impair glucose-stimulated insulin release. Diabetes. 2003;52(7):1695-700. PMCID: 1403824. 
13. 
Lee GA, Schwarz JM, Patzek S, Kim S, Dyachenko A, Wen M, et al. The acute effects of 
HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men. 
Journal of acquired immune deficiency syndromes (1999). 2009;52(2):246-8. PMCID: 3164488. 
14. 
Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondrial toxicity in HAART: an overview 
of in vitro evidence. Curr Pharm Des.17(20):2130-44. 
15. 
Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure 
to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance 
markers in the Multicenter AIDS Cohort Study. AIDS (London, England). 2005;19(13):1375-83. 
16. 
Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al. Antiretroviral 
therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 
(London, England). 2007;21(13):1739-45. 
17. 
Cade WT, Reeds DN, Mittendorfer B, Patterson BW, Powderly WG, Klein S, et al. Blunted 
lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART. 
American journal of physiology. 2007;292(3):E812-9. 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
30 
 
18. 
Driscoll SD, Meininger GE, Ljungquist K, Hadigan C, Torriani M, Klibanski A, et al. 
Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human 
immunodeficiency virus-infected patients. The Journal of clinical endocrinology and metabolism. 
2004;89(5):2171-8. 
19. 
Djedaini M, Peraldi P, Drici MD, Darini C, Saint-Marc P, Dani C, et al. Lopinavir co-induces 
insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun. 
2009;386(1):96-100. 
20. 
Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al. Nelfinavir, 
A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic 
reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 
2007;13(17):5183-94. 
21. 
Kraus M, Malenke E, Gogel J, Muller H, Ruckrich T, Overkleeft H, et al. Ritonavir induces 
endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. 
Mol Cancer Ther. 2008;7(7):1940-8. 
22. 
Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC. HIV-1 protease inhibitors 
nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum 
stress. Cancer Res. 2007;67(22):10920-8. 
23. 
Wu X, Sun L, Zha W, Studer E, Gurley E, Chen L, et al. HIV protease inhibitors induce 
endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. 
Gastroenterology.138(1):197-209. 
24. 
Zhang S, Carper MJ, Lei X, Cade WT, Yarasheski KE, Ramanadham S. Protease 
inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway 
and compromise insulin secretion. American journal of physiology. 2009;296(4):E925-35. 
25. 
Zhou H, Pandak WM, Jr., Lyall V, Natarajan R, Hylemon PB. HIV protease inhibitors 
activate the unfolded protein response in macrophages: implication for atherosclerosis and 
cardiovascular disease. Mol Pharmacol. 2005;68(3):690-700. 
26. 
Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, et al. Endoplasmic reticulum stress 
plays a central role in development of leptin resistance. Cell Metab. 2009;9(1):35-51. 
27. 
Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum 
stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306(5695):457-61. 
28. 
Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical 
chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 
diabetes. Science. 2006;313(5790):1137-40. 
29. 
Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, et al. Management 
of metabolic complications associated with antiretroviral therapy for HIV-1 infection: 
recommendations of an International AIDS Society-USA panel. Journal of acquired immune 
deficiency syndromes (1999). 2002;31(3):257-75. 
30. 
Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary 
care guidelines for the management of persons infected with human immunodeficiency virus: 
2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin 
Infect Dis. 2009;49(5):651-81. 
31. 
Engelson ES, Agin D, Kenya S, Werber-Zion G, Luty B, Albu JB, et al. Body composition 
and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. 
Metabolism: clinical and experimental. 2006;55(10):1327-36. 
32. 
Yarasheski KE, Cade WT, Overton ET, Mondy KE, Hubert S, Laciny E, et al. Exercise 
training augments the peripheral insulin sensitizing effects of pioglitazone in HIV-infected adults 
with insulin resistance and central adiposity. American journal of physiology. 
33. 
Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL, et al. Effects 
of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated 
waist/hip ratio. AIDS (London, England). 2007;21(1):47-57. 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
31 
 
34. 
Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of 
rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 
2004;140(10):786-94. 
35. 
Tomazic J, Karner P, Vidmar L, Maticic M, Sharma PM, Janez A. Effect of metformin and 
rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing 
HAART. Acta Dermatovenerol Alp Panonica Adriat. 2005;14(3):99-105. 
36. 
Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the 
treatment of HIV lipodystrophy syndrome: A randomized controlled trial. Jama. 2000;284(4):472-
7. 
37. 
Yarasheski KE, Cade WT, Overton ET, Mondy KE, Hubert S, Laciny E, et al. Exercise 
training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults 
with insulin resistance and central adiposity. American journal of physiology.300(1):E243-51. 
PMCID: 3023206. 
38. 
Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Boutekatjirt A, et al. Effect of 
pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial 
(ANRS 113). Antiviral therapy. 2008;13(1):67-76. 
39. 
DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. 
Pioglitazone for diabetes prevention in impaired glucose tolerance. The New England journal of 
medicine.364(12):1104-15. 
40. 
Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, Jr., et al. Risk 
of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal 
cohort study. Diabetes care.34(4):916-22. PMCID: 3064051. 
41. 
Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone 
use and bladder cancer through drug adverse event reporting. Diabetes care.34(6):1369-71. 
PMCID: 3114317. 
42. 
Han JH, Crane HM, Bellamy SL, Frank I, Cardillo S, Bisson GP. HIV infection and glycemic 
response to newly initiated diabetic medical therapy. AIDS (London, England).26(16):2087-95. 
43. 
Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, et al. 
Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity 
in obese men and women. Diabetes.59(8):1899-905. PMCID: 2911053. 
44. 
Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids 
induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 
2006;439(7075):484-9. 
45. 
Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile 
acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167-77. PMCID: 2739652. 
46. 
Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, et al. Lowering bile 
acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes 
through reduced energy expenditure. J Biol Chem.286(30):26913-20. PMCID: 3143650. 
47. 
Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile 
acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. The Journal of 
clinical investigation. 2004;113(10):1408-18. PMCID: 406532. 
48. 
Gregor MG, Hotamisligil GS. Adipocyte stress: The endoplasmic reticulum and metabolic 
disease. J Lipid Res. 2007. 
49. 
Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. 
Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte 
fatty acid binding protein. Science. 1996;274(5291):1377-9. 
50. 
Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-
mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced 
insulin resistance. Science. 1996;271(5249):665-8. 
51. 
Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role 
for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333-6. 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
32 
 
52. 
Seyhun E, Malo A, Schafer C, Moskaluk CA, Hoffmann RT, Goke B, et al. 
Tauroursodeoxycholic acid reduces endoplasmic reticulum stress, acinar cell damage, and 
systemic inflammation in acute pancreatitis. Am J Physiol Gastrointest Liver Physiol.301(5):G773-
82. 
53. 
Malo A, Kruger B, Seyhun E, Schafer C, Hoffmann RT, Goke B, et al. 
Tauroursodeoxycholic acid reduces endoplasmic reticulum stress, trypsin activation, and acinar 
cell apoptosis while increasing secretion in rat pancreatic acini. Am J Physiol Gastrointest Liver 
Physiol.299(4):G877-86. 
54. 
Lindl KA, Akay C, Wang Y, White MG, Jordan-Sciutto KL. Expression of the endoplasmic 
reticulum stress response marker, BiP, in the central nervous system of HIV-positive individuals. 
Neuropathol Appl Neurobiol. 2007;33(6):658-69. 
55. 
Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic 
syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin 
Infect Dis. 2007;44(5):726-34. 
56. 
Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, et al. Effects of ritonavir and 
amprenavir 
on 
insulin 
sensitivity 
in 
healthy 
volunteers. 
AIDS (London, 
England). 
2007;21(16):2183-90. PMCID: 3167072. 
57. 
Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, et al. Metabolic 
Syndrome Before and After Initiation of Antiretroviral Therapy in Treatment-Naive HIV-Infected 
Individuals. Journal of acquired immune deficiency syndromes (1999).61(3):381-9. PMCID: 
3480980. 
58. 
De Coppi P, Milan G, Scarda A, Boldrin L, Centobene C, Piccoli M, et al. Rosiglitazone 
modifies the adipogenic potential of human muscle satellite cells. Diabetologia. 2006;49(8):1962-
73. 
59. 
Musaro A, Barberi L. Isolation and culture of mouse satellite cells. Methods Mol 
Biol.633:101-11. 
60. 
Chen L, Jarujaron S, Wu X, Sun L, Zha W, Liang G, et al. HIV protease inhibitor lopinavir-
induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK 
signaling pathways in macrophages. Biochem Pharmacol. 2009;78(1):70-7. PMCID: 2704357. 
61. 
Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, et al. Doxycycline plus 
tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid.19 Suppl 1:34-
6. 
62. 
Batta AK, Salen G, Shefer S, Tint GS, Dayal B. The effect of tauroursodeoxycholic acid 
and taurine supplementation on biliary bile acid composition. Hepatology. 1982;2(6):811-6. 
63. 
Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, et al. 
Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig 
Dis Sci. 1996;41(4):809-15. 
64. 
Setchell KD, Rodrigues CM, Podda M, Crosignani A. Metabolism of orally administered 
tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut. 1996;38(3):439-46. 
PMCID: 1383076. 
65. 
Larghi A, Crosignani A, Battezzati PM, De Valle G, Allocca M, Invernizzi P, et al. 
Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a 
pilot crossover study. Aliment Pharmacol Ther. 1997;11(2):409-14. 
66. 
Angelico M, Tisone G, Baiocchi L, Palmieri G, Pisani F, Negrini S, et al. One-year pilot 
study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation. Ital J 
Gastroenterol Hepatol. 1999;31(6):462-8. 
67. 
Report of the expert committee on the diagnosis and classification of diabetes mellitus. 
Diabetes care. 2003;26 Suppl 1:S5-20. 
68. 
Genton L, Hans D, Kyle UG, Pichard C. Dual-energy X-ray absorptiometry and body 
composition: differences between devices and comparison with reference methods. Nutrition. 
2002;18(1):66-70. 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
33 
 
69. 
Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations 
in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver 
disease. Gastroenterology. 2008;134(2):424-31. 
70. 
Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, Muscle, and Adipose Tissue 
Insulin Action Is Directly Related to Intrahepatic Triglyceride Content in Obese Subjects. 
Gastroenterology. 2008;134:1369-75. 
71. 
Frimel TN, Deivanayagam S, Bashir A, O'Connor R, Klein S. Assessment of intrahepatic 
triglyceride content using magnetic resonance spectroscopy. J Cardiometab Syndr. 
2007;2(2):136-8. 
72. 
Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production 
during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled 
exogenous glucose infusates. Diabetes. 1987;36(8):914-24. 
73. 
Fabbrini E, deHaseth D, Deivanayagam S, Mohammed BS, Vitola BE, Klein S. Alterations 
in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content. Obesity 
(Silver Spring). 2009;17(1):25-9. 
74. 
Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and 
carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology. 
2009;136(5):1552-60. 
75. 
Patterson BW, Zhao G, Elias N, Hachey DL, Klein S. Validation of a new procedure to 
determine plasma fatty acid concentration and isotopic enrichment. J Lipid Res. 
1999;40(11):2118-24. 
76. 
Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. 
Ann N Y Acad Sci. 1959;82:420-30. 
77. 
Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandam N, LaRiviere LL, et al. A 
potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and 
obesity-related diabetes. Cell Metab. 2005;1(2):133-44. 
78. 
Chen Z, Gropler MC, Mitra MS, Finck BN. Complex Interplay between the Lipin 1 and the 
Hepatocyte Nuclear Factor 4 alpha (HNF4alpha) Pathways to Regulate Liver Lipid Metabolism. 
PLoS One.7(12):e51320. PMCID: 3517414. 
79. 
Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, et al. Lipin 1 is an 
inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 
2006;4(3):199-210. 
80. 
Chen Z, Vigueira PA, Chambers KT, Hall AM, Mitra MS, Qi N, et al. Insulin resistance and 
metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-
activated receptor gamma-sparing thiazolidinedione. J Biol Chem.287(28):23537-48. PMCID: 
3390629. 
81. 
Xiang X, Han Y, Neuvonen M, Laitila J, Neuvonen PJ, Niemi M. High performance liquid 
chromatography-tandem mass spectrometry for the determination of bile acid concentrations in 
human plasma. J Chromatogr B Analyt Technol Biomed Life Sci.878(1):51-60. 
82. 
Chen Z, Gropler MC, Norris J, Lawrence JC, Jr., Harris TE, Finck BN. Alterations in hepatic 
metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion. 
Arteriosclerosis, thrombosis, and vascular biology. 2008;28(10):1738-44. PMCID: 2655237. 
83. 
Gropler MC, Harris TE, Hall AM, Wolins NE, Gross RW, Han X, et al. Lipin 2 is a liver-
enriched phosphatidate phosphohydrolase enzyme that is dynamically regulated by fasting and 
obesity in mice. J Biol Chem. 2009;284(11):6763-72. PMCID: 2652272. 
84. 
Chen Z, Norris JY, Finck BN. Peroxisome proliferator-activated receptor-gamma 
coactivator-1alpha (PGC-1alpha) stimulates VLDL assembly through activation of cell death-
inducing DFFA-like effector B (CideB). J Biol Chem.285(34):25996-6004. PMCID: 2923994. 
85. 
Mitra MS, Schilling JD, Wang X, Jay PY, Huss JM, Su X, et al. Cardiac lipin 1 expression 
is regulated by the peroxisome proliferator activated receptor gamma coactivator 1alpha/estrogen 
related receptor axis. J Mol Cell Cardiol.51(1):120-8. PMCID: 3104300. 


Tauroursodeoxycholic acid for protease-inhibitor associated insulin resistance 
PI: Reeds 
34 
 
86. 
Mitra MS, Chen Z, Ren H, Harris TE, Chambers KT, Hall AM, et al. Mice with an adipocyte-
specific lipin 1 separation-of-function allele reveal unexpected roles for phosphatidic acid in 
metabolic regulation. Proc Natl Acad Sci U S A. 
87. 
Coughlin CC, Finck BN, Eagon JC, Halpin VJ, Magkos F, Mohammed BS, et al. Effect of 
marked weight loss on adiponectin gene expression and plasma concentrations. Obesity (Silver 
Spring, Md. 2007;15(3):640-5. 
88. 
Adler-Wailes DC, Guiney EL, Koo J, Yanovski JA. Effects of ritonavir on adipocyte gene 
expression: 
evidence 
for 
a 
stress-related 
response. 
Obesity 
(Silver 
Spring, 
Md. 
2008;16(10):2379-87. PMCID: 2614385. 
89. 
Parker RA, Flint OP, Mulvey R, Elosua C, Wang F, Fenderson W, et al. Endoplasmic 
reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by 
HIV protease inhibitors. Mol Pharmacol. 2005;67(6):1909-19. 
90. 
Reeds DN, Patterson BW, Okunade A, Holloszy JO, Polonsky KS, Klein S. Ginseng and 
ginsenoside Re do not improve beta-cell function or insulin sensitivity in overweight and obese 
subjects with impaired glucose tolerance or diabetes. Diabetes care.34(5):1071-6. PMCID: 
3114517. 
91. 
Magkos F, Fabbrini E, Korenblat K, Okunade AL, Patterson BW, Klein S. Reproducibility 
of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with 
non-alcoholic fatty liver disease. Int J Obes (Lond).35(9):1233-40. 
92. 
Gregor MF, Yang L, Fabbrini E, Mohammed BS, Eagon JC, Hotamisligil GS, et al. 
Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes. 
2009;58(3):693-700. PMCID: 2646068. 
93. 
Cade WT, Reeds DN, Mondy KE, Overton ET, Grassino J, Tucker S, et al. Yoga lifestyle 
intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk 
factors. HIV medicine.